233552 | Cobra Venom Factor, Naja naja kaouthia

233552
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      233552-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewNative cobra venom factor from Naja naja kaouthia. Glycoprotein composed of three non-identical disulfide-bonded subunits with M.W. of 68 kDa (α), 48 kDa (β), and 30 kDa (γ). Cobra venom factor (CVF) is a structural and functional analog of cobra, as well as mammalian C3. Thus, in the presence of Factor B, Factor D, and Mg2+, CVF can form a stable CVF,Bb complex that is a C3/C5 convertase enzyme; however, the CVF,Bb complex is not susceptible to regulation by Factors H and I. Four to six µg of purified CVF are equal to 1.0 unit of functional activity as measured by the method of Cochrane, et al.
          Catalogue Number233552
          Brand Family Calbiochem®
          SynonymsCobra Venom Anticomplementary Protein
          References
          ReferencesBogers, W.M., et al. 1993. Eur. J. Immunol. 23, 433.
          Fritzinger, D.C., et al. 1992. J. Immunol. 149, 3554.
          Muller, B. and Muller-Ruchholtz, W. 1987. Leuk. Res. 11, 461.
          Vogel, C.W. and Muller-Eberhard, H.J. 1984. J. Immunol. Methods 73, 203.
          Cochrane, C.G., et al. 1970. J. Immunol. 105, 55.
          Ballows, M. and Cochrane, C.G. 1969. J. Immunol. 103, 944.
          Product Information
          Activity≥250 units/ml
          DeclarationNot available for sale outside the United States.
          FormLiquid
          FormulationIn PBS, pH 7.2.
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          ContaminantsPhospholipase: none detected
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 20/21/22

          Harmful by inhalation, in contact with skin and if swallowed.
          S PhraseS: 36

          Wear suitable protective clothing.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Harmful
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          233552

          References

          Reference overview
          Bogers, W.M., et al. 1993. Eur. J. Immunol. 23, 433.
          Fritzinger, D.C., et al. 1992. J. Immunol. 149, 3554.
          Muller, B. and Muller-Ruchholtz, W. 1987. Leuk. Res. 11, 461.
          Vogel, C.W. and Muller-Eberhard, H.J. 1984. J. Immunol. Methods 73, 203.
          Cochrane, C.G., et al. 1970. J. Immunol. 105, 55.
          Ballows, M. and Cochrane, C.G. 1969. J. Immunol. 103, 944.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision20-December-2010 JSW
          SynonymsCobra Venom Anticomplementary Protein
          DescriptionNative cobra venom factor from Naja naja kaouthia. Glycoprotein composed of three nonidentical disulfide-bound subunits with M.W. of 68,000 (α), 48,000 (β), and 30,000 (γ). Cobra Venom Factor (CVF) is a structural and functional analog of cobra, as well as mammalian C3. In the presence of Factor B, Factor D, and Mg2+, CVF can form a stable CVF, Bb complex which is a C3/C5 convertase enzyme; however, the CVF,Bb complex is not susceptible to regulation by Factors H and I. Four to six µg of purified CVF is equal to 1.0 unit of functional activity as measured by the method of Cochrane, et al.
          FormLiquid
          FormulationIn PBS, pH 7.2.
          Concentration Label Please refer to vial label for lot-specific concentration
          Purity≥95% by SDS-PAGE
          ContaminantsPhospholipase: none detected
          Activity≥250 units/ml
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Harmful
          ReferencesBogers, W.M., et al. 1993. Eur. J. Immunol. 23, 433.
          Fritzinger, D.C., et al. 1992. J. Immunol. 149, 3554.
          Muller, B. and Muller-Ruchholtz, W. 1987. Leuk. Res. 11, 461.
          Vogel, C.W. and Muller-Eberhard, H.J. 1984. J. Immunol. Methods 73, 203.
          Cochrane, C.G., et al. 1970. J. Immunol. 105, 55.
          Ballows, M. and Cochrane, C.G. 1969. J. Immunol. 103, 944.